From Wikipedia, the free encyclopedia
  (Redirected from JNJ26990990)
Jump to: navigation, search
Clinical data
Synonyms N-((Benzo[b]thien-3-yl)methyl)sulfamide
CAS Number
PubChem CID
Chemical and physical data
Formula C9H10N2O2S2
Molar mass 242.3179 g/mol
 NYesY (what is this?)  (verify)

JNJ-26990990 is a broad-spectrum anticonvulsant drug currently under development by Janssen Pharmaceutica as a second-generation followup to the marketed drug topiramate.[1][2] It was designed to have the same anticonvulsant effects as topiramate, but without the side effects associated with topiramate's carbonic anhydrase inhibition.[1] It also has potential use in the treatment of inflammatory pain, neuropathic pain, and depression.[3]

JNJ-26990990 entered phase II clinical trials in October 2007.[4]

Metabolites and radioactive isotope-labeled derivatives of JNJ-26990990 have also been prepared to support its development.[5]

See also[edit]


  1. ^ a b Michael H. Parker, et al. (2009). "Novel, Broad-Spectrum Anticonvulsants Containing a Sulfamide Group: Advancement of N-((Benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into Human Clinical Studies". Journal of Medicinal Chemistry. 52 (23): 7528–36. doi:10.1021/jm801432r. PMID 19388676. 
  2. ^ WO patent 2006023861, Parker, Michael H.; Reitz, Allen B.; Maryanoff, Bruce E., "Preparation of benzo-fused heteroaryl sulfamide derivatives for the treatment of epilepsy and related disorders", issued 2006-03-02, assigned to Janssen Pharmaceutica 
  3. ^ "JNJ 26990990 Johnson & Johnson developing anticonvulsant Johnson & Johnson preclinical data". R & D Focus Drug News. September 22, 2008. 
  4. ^ János Fischer and C. Robin Ganellin (2010). "Chapter 2. Standalone Drugs". Analogue-Based Drug Discovery II. doi:10.1002/9783527630035.ch2. 
  5. ^ Lin, Ronghui; Weaner, Larry E.; Hoerr, David C.; Salter, Rhys; Gong, Yong (2013). "Expeditious syntheses of stable and radioactive isotope-labeled anticonvulsant agent, JNJ-26990990, and its metabolites". Journal of Labelled Compounds and Radiopharmaceuticals. 56: 22. doi:10.1002/jlcr.3013.